Literature DB >> 27566080

RRM1, RRM2 and ERCC2 Gene Polymorphisms in Coronary Artery Disease.

Emre Murat Altinkilic1, Selim Isbir2, Uzay Gormus3, Seda Gulec Yilmaz1, Altay Burak Dalan4, Selvi Duman2, Turgay Isbir5.   

Abstract

BACKGROUND/AIM: Coronary artery disease (CAD) is a chronic inflammatory disease seen as formation of atherosclerotic plaques (atheroma) in coronary arteries. Recent published papers show that DNA damage and repair mechanisms play a crucial role on the development and severity of atheromas. In this study, we investigated nucleotide excision repair (NER) pathway-related gene polymorphisms in atherosclerosis. XPD, encoded by ERCC2 gene, is an ATP-depended helicase enzyme involved in the NER pathway. Ribonucleotide reductase (RR) is a tetra meric enzyme, synthesizing deoxyribonucleotides from ribonucleotides for DNA synthesis. RR is encoded by the RRM1 and RRM2 genes, which are two subunits of RR enzyme.
MATERIALS AND METHODS: DNA samples isolated from peripheral blood were genotyped with real-time polymerase chain reaction (RT-PCR) for RRM1 (rs12806698), RRM2(rs6859180) and ERCC2 (rs13181) genes.
RESULTS: The frequency of the RRM1 AC heterozygote genotype was found to be significantly lower (odds ratio (OR)=0.369, 95% confidence interval (CI)=0.179-0.760; p=0.006), whereas the CC homozygote genotype was found to be significantly higher in patients compared to controls (OR=7.636, 95% CI=2.747-21.229; p=0.000). In addition, the RRM1 A allele was higher in control group (p=0.000, OR=0.131 95%CI=0.047-0.364). For the ERCC2 gene, GG genotype was significantly higher in control group (p=0.017, OR=0.387, 95%CI=0.175-0.152) and TT genotype (p=0.021) was higher in CAD group. TT genotype had a ~3-fold increased risk (OR=3.615, 95%CI=1.148-11.380) for CAD. Carrying T allele appears to be a risk factor for CAD (p=0.017, OR=2.586, 95%CI=1.173-5.699), while the G allele might be a risk-reducing factor (p=0.021, OR=0.277, 95%CI=0.088-0.871) for CAD.
CONCLUSION: RRM1 and ERCC gene polymorphisms, having homozygous mutant genotype, might be a risk factor for CAD. RRM1 and ERCC wild type alleles are risk-reducing factor for CAD. Also, carrying RRM1 A allele might have a protective effect for smokers.
Copyright © 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  CAD; ERCC2; RRM1; RRM2; polymorphism

Mesh:

Substances:

Year:  2016        PMID: 27566080

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  5 in total

1.  Role of Xeroderma Pigmentosum Group D in Cell Cycle and Apoptosis in Cutaneous Squamous Cell Carcinoma A431 Cells.

Authors:  Ou-Gen Liu; Xiao-Yan Xiong; Chun-Ming Li; Xian-Sheng Zhou; Si-Si Li
Journal:  Med Sci Monit       Date:  2018-01-24

2.  Bioinformatics analysis of the circRNA-miRNA-mRNA network for non-small cell lung cancer.

Authors:  Xueying Cai; Lixuan Lin; Qiuhua Zhang; Weixin Wu; An Su
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

3.  Genetic Variants Associated with Chronic Kidney Disease in a Spanish Population.

Authors:  Zuray Corredor; Miguel Inácio da Silva Filho; Lara Rodríguez-Ribera; Antonia Velázquez; Alba Hernández; Calogerina Catalano; Kari Hemminki; Elisabeth Coll; Irene Silva; Juan Manuel Diaz; José Ballarin; Martí Vallés Prats; Jordi Calabia Martínez; Asta Försti; Ricard Marcos; Susana Pastor
Journal:  Sci Rep       Date:  2020-01-10       Impact factor: 4.379

4.  Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia.

Authors:  Hanxi Yu; Shuangshuang Wu; Shuang Liu; Xinyu Li; Yuqing Gai; Hai Lin; Yue Wang; Holly Edwards; Yubin Ge; Guan Wang
Journal:  J Cell Mol Med       Date:  2022-03-31       Impact factor: 5.295

5.  Identification and validation of a ferroptosis-related gene to predict survival outcomes and the immune microenvironment in lung adenocarcinoma.

Authors:  Biao Deng; Jing Xiang; Zhu Liang; Lianxiang Luo
Journal:  Cancer Cell Int       Date:  2022-09-24       Impact factor: 6.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.